Clinigence Holdings earnings date
Want to see NUTX full AI Analyst Report?
Clinigence Holdings (NUTX) Q3 2026 Earnings Report
NUTX Q3 2026 EPS Results
- Actual EPS
- $5.71
- Consensus EPS
- $5.54
- Beat/Miss
- Beat by +$0.17
- One Year Ago EPS
- $7.76
NUTX Q3 2026 Revenue Results
- Actual Revenue
- $217.61M
- Expected Revenue
- $214.82M
- Beat/Miss
- Beat by +$2.79M
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Clinigence Holdings's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was broadly positive, supported by strong hospital visit growth, higher net income, substantial cash generation, a growing development pipeline, favorable IDR litigation outcomes and continued investment in operations and technology. However, the company reported significant year-over-year declines in revenue and adjusted EBITDA, lower third-quarter profitability metrics, higher expense ratios, slightly weaker physician collections and ongoing reimbursement and legislative uncertainty. Overall, the positive operational, cash flow and strategic developments outweighed the stated financial and regulatory challenges.
Management expects San Antonio and Jacksonville to open in the fourth quarter of 2026, with 4 additional projects under active construction expected to be completed in late 2027 and early 2028; it is also targeting 3 to 5 hospitals per year, building one to two new IPAs around its hospitals every year, and expects revenue per visit to remain in a range from about $3,800 to $4,200, with the possibility of being on the lower end or potentially trending up. Contract services are expected to remain in the same type of range in relation to revenue, following a reduction from upwards close to $60 million or so, while noncontrolling interest is expected to remain in the high teens to maybe low 20% in relation to gross profit. The company has not given any specific guidance for contract services, and said there is a good chance it will start providing more detail on 2027 after finishing out the year.
- Higher Nine-Month Net IncomeNet income attributable to Nutex increased to $152.9 million for the first three quarters of 2026, up 159% from $59 million in the same period of 2025. Management attributed support for earnings to lower earn-out expenses as most legacy facilities completed vesting and lower arbitration-related costs following the renegotiation of the HALO MD contract.
- Strong Hospital Volume GrowthHospital visits increased 10.2% to 154,300 during the first nine months of 2026 from 140,100 in the same period of 2025, with same-hospital growth of 6.3%. In the third quarter, hospital visits increased 18.1% to 54,622, while same-hospital visits increased 12.4%.
- Improved Cash Position and Operating Cash FlowCash on hand grew to $249.9 million as of September 30, 2026, from $185.6 million at year-end 2025. Net cash from operating activities increased 6% to $188.1 million for the first nine months, compared with $177.7 million in 2025.
- Solid Balance Sheet and CollectionsTotal assets were just above $1 billion at September 30, 2026. Accounts receivable increased by $36.6 million to $356.1 million, and management said the company had another strong collection quarter. Net long-term debt remained relatively low at $34.2 million compared with the company's revenue and expansion pace.
- Population Health Revenue GrowthPopulation Health revenue increased approximately 14% to $26.3 million for the first nine months of 2026 from $23.1 million in the same period of 2025, and increased approximately 13% to $8.5 million in the third quarter from $7.6 million in the prior-year quarter.
- Expansion of Population Health PlatformThe Population Health Management division oversees almost 40,000 members across Medicare Advantage, commercial and Medicaid managed care programs. Nutex operates IPAs in Southern California, Houston, Phoenix and South Florida, and has established additional IPAs in Dallas and San Antonio with plans to enroll patients in 2027.
- Hospital Development PipelineTwo facilities in San Antonio, Texas, and Jacksonville, Florida, were expected to open in the fourth quarter of 2026. Four additional projects were under active construction, with expected completion in late 2027 and early 2028. Management also said it continues to target three to five hospitals per year for external growth.
- Continued Investment in Technology and Clinical CapabilitiesNutex said it continues to invest in technology, diagnostics, artificial intelligence, automation and differentiated patient services. The company is expanding advanced diagnostic imaging, specialty services, observation and inpatient care to broaden the services available at its hospitals.
- Business Development Supporting Volume GrowthManagement said investments in business development, targeted marketing, local leadership and expanded services directly contributed to hospital growth. Each facility has local business development leadership, supported by a corporate structure that coordinates strategy and shares best practices.
- Favorable IDR Results and CollectionsApproximately 50% to 60% of company-billable visits are submitted through the IDR process, with 40% to 50% of all billable visits resulting in an award determination. Nutex prevailed in over 80% of those determinations over the last nine months and collected on average over 80% of award amounts calculated from awards from inception through March 2026.
- Provider-Favorable IDR Court DecisionsFederal courts in California, Florida, Pennsylvania, Texas, Connecticut, Georgia and Virginia issued decisions reinforcing the finality of IDR awards and limiting insurers' ability to challenge arbitration outcomes. Management said these rulings support enforcement of the No Surprises Act's payment and arbitration requirements.
- Fifth Circuit QPA DecisionThe U.S. Court of Appeals for the Fifth Circuit ruled in favor of the Texas Medical Association and other plaintiffs on two of three issues involving calculation of the qualifying payment amount. Management viewed the decision as progress toward a more transparent and balanced reimbursement framework.
- Lower Contract Services and Stock Compensation CostsContract services declined during the first nine months, primarily because of the reduction in the CMS fee and the amended HALO MD contract. Stock compensation expense fell to $6.4 million from $119.6 million in the prior-year period, a decrease of $113.2 million.
- Workforce Stability and Patient SatisfactionEmployee turnover was 9.6% through the first nine months of 2026. Hospitals maintained an average Google rating of 4.76 stars, which management said reflected continued patient-centered care and workforce stability.
- Profitability Across Mature HospitalsManagement said all mature hospitals were profitable. Of the three hospitals opened in the prior year—Archview, St. Louis, Red River in Sherman, Texas, and Humble in Houston—two of the three were already profitable.
NUTX Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 5.87- | 1.69 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 5.545.71 | 7.76 | -26.42% (-2.05) | |
| Aug 06, 2026 | 2026 (Q2) | 4.959.38 | -2.95 | 417.97% (+12.33) | |
| Apr 30, 2026 | 2026 (Q1) | 3.996.52 | 2.56 | 154.69% (+3.96) | |
| Mar 05, 2026 | 2025 (Q4) | 5.561.69 | 11.12 | -84.78% (-9.43) | |
| Nov 19, 2025 | 2025 (Q3) | ―- | -1.72 | ― | |
| Nov 18, 2025 | 2025 (Q2) | 1.817.76 | -1.72 | 551.16% (+9.48) | |
| May 13, 2025 | 2025 (Q1) | ―- | -0.1 | ― | |
| Mar 31, 2025 | 2024 (Q4) | 3.042.56 | -0.1 | 2660.00% (+2.66) | |
| Nov 07, 2024 | 2024 (Q3) | -0.24-1.72 | -1.5 | -14.67% (-0.22) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
